Exchange: NASDAQ·Updated 07:30 PM EST

IPSC News

News
all
press releases
HC Wainwright Issues Pessimistic Forecast for IPSC Earnings
Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) - Equities researchers at HC Wainwright decreased their FY2027 EPS estimates for Century Therapeutics in a research report issued to clients and investors on Friday, November 13th. HC Wainwright analyst M. Kapoor now anticipates that the company...
MarketBeat
HC Wainwright Issues Pessimistic Forecast for IPSC Earnings
Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) - Equities researchers at HC Wainwright decreased their FY2027 EPS estimates for Century Therapeutics in a research report issued to clients and investors on Friday, November 13th. HC Wainwright analyst M. Kapoor now anticipates that the company...
MarketBeat
More News
Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.
Stocktwits
Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses...
Yahoo! Finance: News
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company PR Newswire SAN FRANCISCO, June 2, 2026 Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)SAN FRANCISCO, June 2...
PR Newswire
Wall Street Zen raised Century Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday...
MarketBeat
Wall Street Zen downgraded shares of Century Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat
Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for shares of Century Therapeutics in a research note issued on...
MarketBeat
Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) has been given an average recommendation of "Hold" by the seven ratings firms that are presently covering the stock, Marketbeat.com reports...
MarketBeat
Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 10,289,543 shares, an increase of 19.3% from the March 15th total of 8,626,834 shares. Based on an average daily volume...
MarketBeat
Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 13th, there was short interest totaling 8,626,834...
MarketBeat

Advertisement|Remove ads.